PreprintReviewVersion 1Preserved in Portico This version is not peer-reviewed
Neoadjuvant Chemotherapy, a Treatment Possibility in Locally Advanced Cervical Cancer, Analysis Focusing on The Outcomes of FIGO Stage III Cervical Carcinoma- a Literature Review
Version 1
: Received: 18 January 2024 / Approved: 19 January 2024 / Online: 19 January 2024 (12:07:26 CET)
How to cite:
Molnar, O.; Mihuțiu, S.; Lazăr, L. Neoadjuvant Chemotherapy, a Treatment Possibility in Locally Advanced Cervical Cancer, Analysis Focusing on The Outcomes of FIGO Stage III Cervical Carcinoma- a Literature Review. Preprints2024, 2024011498. https://doi.org/10.20944/preprints202401.1498.v1
Molnar, O.; Mihuțiu, S.; Lazăr, L. Neoadjuvant Chemotherapy, a Treatment Possibility in Locally Advanced Cervical Cancer, Analysis Focusing on The Outcomes of FIGO Stage III Cervical Carcinoma- a Literature Review. Preprints 2024, 2024011498. https://doi.org/10.20944/preprints202401.1498.v1
Molnar, O.; Mihuțiu, S.; Lazăr, L. Neoadjuvant Chemotherapy, a Treatment Possibility in Locally Advanced Cervical Cancer, Analysis Focusing on The Outcomes of FIGO Stage III Cervical Carcinoma- a Literature Review. Preprints2024, 2024011498. https://doi.org/10.20944/preprints202401.1498.v1
APA Style
Molnar, O., Mihuțiu, S., & Lazăr, L. (2024). Neoadjuvant Chemotherapy, a Treatment Possibility in Locally Advanced Cervical Cancer, Analysis Focusing on The Outcomes of FIGO Stage III Cervical Carcinoma- a Literature Review. Preprints. https://doi.org/10.20944/preprints202401.1498.v1
Chicago/Turabian Style
Molnar, O., Simona Mihuțiu and Liviu Lazăr. 2024 "Neoadjuvant Chemotherapy, a Treatment Possibility in Locally Advanced Cervical Cancer, Analysis Focusing on The Outcomes of FIGO Stage III Cervical Carcinoma- a Literature Review" Preprints. https://doi.org/10.20944/preprints202401.1498.v1
Abstract
Abstract: Cervical cancer, which is the fourth most common malignancy and the fourth greatest cause of cancer-related deaths in women globally, continues to be a serious issue for global health. Despite advancements in treatment techniques, particularly the implementation of concomitant chemoradiation therapy, predicting the prognosis of locally advanced cervical cancer, especially for stage III, remains challenging. In recent years, neoadjuvant chemotherapy (NACT) has gained interest as a viable treatment strategy. The objective of this review paper is to scrutinize the clinical data and outcomes associated with NACT in the management of stage 3 cervical cancer. Electronic databases were used to perform a comprehensive literature search, and research up to 2023 were included. The findings suggest that NACT followed by irradiation may have advantages such as lowering tumor size, pelvic architectural distortion, and subclinical distant metastases, therefore enhancing radiation delivery. However, several studies have produced conflicting findings, raising questions regarding toxicity and finding no appreciable survival benefit over radiation alone. NACT followed by radical surgery has demonstrated more promising outcomes compared to surgery alone in terms of increasing rates of overall survival (OS) and progression-free survival (PFS). Additionally, NACT has been associated with decreased tumor growth, parametrial infiltration, nodal, metastases, and vascular space invasion. These findings suggest adjuvant radiation treatment. Although the overall survival rate has been markedly increased by concomitant chemoradiation treatment, metastatic disease continues to be a major factor in the death rate from cervical cancer. Therefore, improving outcomes in locally advanced cervical cancer requires investigating novel systemic treatments, such as NACT. The study also emphasizes how crucial it is to research factors like cisplatin dose-intensity and cycle lengths in order to maximize NACT's efficacy. To prevent the need for subsequent treatments and cumulative toxicity, more study should concentrate on patient selection for NACT followed by surgery.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
